Vector Therapeutics Information

Vector Therapeutics is a fully-reporting, public-ready, commercial-stage specialty pharmaceutical company. We are focused on acquiring, developing, and commercializing life-changing treatments for a variety of cancers, with a primary focus on leukemia. Our broader focus is precision immunotherapy and its application to both hematology and solid tumors. Our product portfolio consists initially of drugs targeting different stages and sub-types of Acute Myeloid Leukemia. We are passionate about our mission to help physicians, caregivers, and patients fight against the deadly outlook of AML. Together we are committed to doing the best to defeat AML in every patient. We believe that precision medicine has the potential to improve treatment outcomes by selecting patients based on their genetic profile and monitoring their status through bio-markers and other advanced methods such as minimal residual disease. We are committed to partnering with physicians, pharmacists, and payors to ensure that every patient has access to the optimal treatment to help them defeat AML. Vector is building a dedicated medical and commercial team in North America and Europe while forming alliances with regional partners to expand access to our drugs. Vector’s management team recently came together with alumni of Amgen, BMS, Celgene, GSK, and Novartis, who have held senior leadership positions in the US and globally and aim to build the next oncology specialty pharmaceutical company with a meaningful impact on the life of patients.